

Quarter End Statement of Investments

1st Quarter as at March 31, 2023

Industry Allocation	% of Net Asset Value	Top 25 Holdings	% of Net Asset Value
Pharmaceuticals and Biotechnology	40.51%	HCA Healthcare, Inc.	2.33%
Medical Equipment and Services	38.86%	Catalent, Inc.	2.33%
Health Care Providers	20.30%	Insulet Corporation	2.30%
Cash & Cash Equivalents	0.83%	Sarepta Therapeutics, Inc.	2.26%
Total	100.50%	QuidelOrtho Corporation	2.21%
Other Assets and Liabilities	(0.50%)	Exact Sciences Corporation	2.19%
Total Net Asset Value	100.00%	Laboratory Corporation of America Holdings	2.07%
		Syneos Health, Inc.	2.06%
		Merck & Co., Inc.	2.03%
		Horizon Therapeutics Plc	2.03%
		Exelixis, Inc.	1.93%
		Universal Health Services, Inc. (Class B)	1.91%
		Elevance Health Inc.	1.90%
		Viatris Inc.	1.83%
		Regeneron Pharmaceuticals, Inc.	1.82%
		Moderna, Inc.	1.81%
		Alnylam Pharmaceuticals, Inc.	1.79%
		Hologic, Inc.	1.72%
		Molina Healthcare, Inc.	1.72%
		Pfizer Inc.	1.69%
		DexCom, Inc.	1.64%
		The Cigna Group	1.64%
		Henry Schein, Inc.	1.63%
		Biogen Inc.	1.60%
		Enovis Corp.	1.60%
		Total Net Asset Value	\$17,631,690

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of March 31, 2023 (unaudited).